Although adeno-associated virus (AAV)-mediated gene therapy has been hindered by the small viral packaging capacity of the vector, trans-splicing AAV vectors are able to package twice the size of the vector genome. Unfortunately, the efficiency of current trans-splicing vectors is very low. Here we show that rational design of the gene splitting site has a profound influence on trans-splicing vector-mediated gene expression. Using mRNA accumulation as a guide, we generated a set of efficient trans-splicing vectors and achieved widespread expression of the 6-kb DH2-R19 mini-dystrophin gene in skeletal muscle of mdx mice, a model for Duchenne muscular dystrophy. The dystrophic phenotype was ameliorated in both adult and aged mice. This demonstrates the use of transsplicing vectors to efficiently express a large therapeutic structural protein. This strategy should be applicable to other large therapeutic genes or large transcription regulatory elements.
Although adeno-associated virus (AAV)-mediated gene therapy has been hindered by the small viral packaging capacity of the vector, trans-splicing AAV vectors are able to package twice the size of the vector genome. Unfortunately, the efficiency of current trans-splicing vectors is very low. Here we show that rational design of the gene splitting site has a profound influence on trans-splicing vector-mediated gene expression. Using mRNA accumulation as a guide, we generated a set of efficient trans-splicing vectors and achieved widespread expression of the 6-kb DH2-R19 mini-dystrophin gene in skeletal muscle of mdx mice, a model for Duchenne muscular dystrophy. The dystrophic phenotype was ameliorated in both adult and aged mice. This demonstrates the use of transsplicing vectors to efficiently express a large therapeutic structural protein. This strategy should be applicable to other large therapeutic genes or large transcription regulatory elements.
AAV is an extremely promising gene therapy vehicle [1] [2] [3] . However, being one of the smallest DNA viruses, it cannot carry a large therapeutic expression cassette. A 5-kb genome is considered the upper limit for a single AAV virion 4 . Based on the inherent capacity of AAV genome concatamerization [5] [6] [7] , the trans-splicing dual vector approach was developed 5 years ago to deliver up to a 10-kb genome [8] [9] [10] [11] . Using this approach, a large gene is split into two parts. The 5¢ gene fragment and a tail-tagged splicing donor sequence are packaged into a donor virus. The 3¢ gene fragment and a preceding splicing acceptor sequence are packaged into an acceptor virus. Protein expression is achieved through co-infection, viral genome recombination and splicing.
Encouraging preliminary results were achieved for certain secreted proteins such as erythropoietin and Factor VIII 8, 12 . Unfortunately, transduction efficiency has been too low to reach the therapeutic level for a structural protein 11 . Moderate improvement was achieved by using novel AAV serotypes or engineering the AAV inverted terminal repeat (ITR) sequence 13, 14 . Nonetheless, the challenge remains to translate the exciting potential of trans-splicing vectors to a real disease model. Recently, our lab and others have systematically investigated the potential barriers 14, 15 . Our results suggest that the accumulation of mRNA, rather than the simultaneous uptake of both donor and acceptor viruses, is the predominant rate-limiting step 15 .
A unique feature of trans-splicing vectors is transcription and splicing across the double-D (dD)-ITR junction in the reconstituted viral genome 6 . We hypothesized that mRNA production in the reconstituted genome is influenced by the DNA sequences flanking the irregular dD-ITR structure. Rational selection of the gene splitting site and optimization of the intron and exon splicing signals may improve overall transduction efficiency of trans-splicing vectors. In this study, we tested this hypothesis with the 6-kb DH2-R19 minidystrophin (DH2) gene.
The DH2 minigene was developed from a truncated, but highly functional, patient-derived gene (Dexon17-48) 16, 17 . The patient with the exon 17-48 deletion displayed an extremely mild phenotype and was ambulant beyond age 60 (ref. 16 ). The DH2 minigene is nearly identical to the full-length dystrophin cDNA except for a perfectly phased deletion in the rod domain (from hinge 2 to spectrin-like repeat 19) . Transgenic expression of the DH2 minigene completely prevented dystrophy in mdx muscle and resulted in muscle strength indistinguishable from that of the wild-type animal 17 . These studies suggest that the DH2 minigene may represent a promising alternative to the full-length cDNA, to rescue dystrophic pathology. Because of the large size of the cDNA, the DH2 minigene represents a great system to explore limitations and improvements in trans-splicing AAV vectors.
To determine the optimal gene splitting site, we first screened the splicing signals from a series of endogenous exon/intron/exon junctions in the DH2 minigene by RNase protection assay (RPA). Considering the size constraint of a single AAV virion, any exon boundary between exons 51 and 65 would be appropriate to divide the DH2 minigene. We initially selected three sites that have the highest consensus splicing values and the most favorable thermodynamic parameters for U1snRNA binding 18 . These exon/intron/exon junctions are 56/56/57, 60/60/61 and 63/63/64. We also picked the 53/53/54 junction, which has an average U1snRNA binding value of the entire dystrophin gene 18 .
We synthesized a series of mini-cassettes to mold the reconstituted viral genomes. Each cassette contained the flanking exon sequences at the putative splitting site, the endogenous intron splicing signals and the dD-ITR junction (Fig. 1a) . We then examined the splicing profile and mRNA accumulation by RPA (Supplementary Methods online) 15 . The 60/60/61 junction had the best calculated splicing value ( Table 1) . Interestingly, the 63/63/64 junction, also a well conserved splicing site, showed the highest splicing efficiency in the RPA (Fig. 1b, Table 1 ). The ratio of spliced to unspliced RNA in p63/63/64 was more than twofold higher than that in p60/60/61. Surprisingly, the 56/56/57 junction was the poorest site. In contrast to the distinctive bands of unspliced and spliced RNA transcripts, our RPA revealed a smear of low molecular weight products from p56/56/ 57 (Fig. 1b) . In addition to quantifying splicing efficiency, we also measured the steady state level of spliced RNA. The 60/60/61 junction yielded the highest level of mRNA, followed by the 63/63/64 junction and the 53/53/54 junction. The 56/56/57 junction produced little detectable spliced transcript (Fig. 1b and Table 1 ).
The RPA results suggest that the 60/60/61 and the 63/63/64 junctions may represent excellent candidate sites to split the minigene. To test whether the unique sequence organization in these locations could overcome the mRNA accumulation barrier, we engineered two pairs of trans-splicing vectors based on the endogenous splicing signals from introns 60 and 63, respectively (Fig. 2a) . The minigene was split precisely between exons 60 and 61, or between exons 63 and 64, as determined by RPA (Fig. 1) . Donor and acceptor viruses were packaged in AAV serotype-6 capsid and delivered either individually or together to the tibialis anterior (TA) and the extensor digitorum longus (EDL) muscles of 2-month-old mdx mice (Supplementary Note and Supplementary Fig. 1 online) . Mini-dystrophin was not detected in muscles infected with a single vector alone (Figs. 2b and 3b, and Supplementary Fig. 2 online) . At 1 month after infection, low levels of the mini-dystrophin protein were found in AV.Donor.63 and AV.Acceptor.63 co-infected muscles (Fig. 2) . The 60/60/61 junction yielded the highest level of mRNA in the RPA (Fig. 1) . Consistent with this result, trans-splicing vectors developed using this junction (AV.Donor.60 and AV.Acceptor.60) yielded significantly higher minidystrophin expression (Fig. 2) . At 3 months after infection, B80% (ranging from 46% to 96%) of myofibers were transduced in the injected TA muscles (Fig. 3a, Supplementary Fig. 2 online) . Importantly, this high level transduction was observed in the absence of a cellular immune response ( Supplementary Fig. 3 online) .
To determine the functional competence of mini-dystrophin produced by trans-splicing vectors, we first evaluated whether it would assemble the dystrophin-associated glycoprotein complex (DGC). The components in all three DGC subcomplexes (the dystroglycan, the sarcoglycan and the cytoplasmic) were restored to the sarcolemma ( Supplementary Fig. 4 online). Consistent with a previous study in the D17-48 minigene transgenic mdx mice 19 , neuronal nitric oxide synthase expression was not restored ( Supplementary Fig. 4 online) .
A more stringent test is to determine whether mini-dystrophin produced by trans-splicing vectors could ameliorate dystrophic pathology and improve muscle strength. We first examined the therapeutic effect in the EDL muscle of 2-month-old mdx mice. On Figure 1 Endogenous splicing signal screening. The RPA was used to evaluate splicing and mRNA accumulation of the selected dystrophin exon/intron/exon junctions in the presence of the dD-ITR structure. (a) Schematic outline of the constructs used in the RPA (not drawn to scale). The endogenous intron splicing sequences were retrieved from genomic DNA by PCR. The dD-ITR was engineered between the 5¢ and the 3¢ splicing signals inside the intron. The location of antisense RPA probes is marked. (b) A representative photomicrograph from six independent RPA experiments. The endogenous human b-actin RNA (the control for RPA and loading) was detected by an independent probe added at the same time. *, the expected location of the RNA transcripts from p56/56/57. average, co-infection led to mini-dystrophin expression in 49% of myofibers (ranging from 12% to 98%) (Fig. 3b,c) . The percentage of centrally nucleated myofibers, a hallmark of muscle degeneration and regeneration, was reduced from 85% in AV.Acceptor.60 infected muscle to 20% in AV.Donor.60 and AV.Acceptor.60 co-infected muscle (Fig. 3c) . Trans-splicing AAV-treated muscle also showed a trend toward increased sarcolemma integrity and mini-dystrophin-positive fibers were completely protected from membrane damage (Fig. 3b,c) .
In a physiology assay, we observed a significant improvement in the specific force of trans-splicing AAV-treated muscle P o 0.018 (Fig. 3c , Supplementary Note and Supplementary Fig. 1 online) . Furthermore, these muscles became more resistant to eccentric contractioninduced injury (Fig. 3c) .
Old mdx muscle displays more severe muscle pathology. To further evaluate our trans-splicing vectors, we infected the EDL muscles of 1-year-old mdx mice. Surprisingly, efficient transduction was achieved at 6 months after infection (Fig. 3d) . On average, the transduction efficiency reached 40% (ranging from 18% to 73%) ( Supplementary  Fig. 5b online) . Despite a quite efficient gene transfer, we only observed moderate improvement in the eccentric contraction assay (Fig. 3d) . Other pathology parameters such as central nucleation, fibrosis and macrophage infiltration were not altered ( Supplementary  Fig. 5 online) . This finding suggests that early intervention may be critical for Duchenne muscular distropy (DMD) gene therapy. Nevertheless, our results in both adult and aged mdx muscles clearly demonstrated the therapeutic potential of trans-splicing AAV vectors for DMD gene therapy.
Until the recent development of dual vector technologies, AAV has been excluded as a candidate vehicle for large therapeutic genes. Transsplicing vectors, though theoretically promising, have so far failed to express a large structure gene at the therapeutic level. We have recently found that the RNA processing represents a crucial barrier to efficient transduction in trans-splicing vectors 15 . Boosting the level of accumulated mRNA may represent a promising avenue to improve transsplicing vector-mediated gene expression. To test this hypothesis, we examined splicing efficiency and mRNA production from a series of exon-intron-exon junctions in the 6-kb mini-dystrophin gene. Consistent with the well-documented observation that RNA transcription and splicing are influenced by DNA sequences 20, 21 , insertion of the dD-ITR junction to different introns resulted in different effects on splicing and mRNA accumulation. Intron 63 was the most efficient splicing site whereas intron 60 yielded the highest level of mRNA. The molecular mechanisms underlying this observation remain to be defined, but it may relate to transcription blocking and/or RNA stability 15, 22 . We also compared protein production between transsplicing vectors that were split at either intron 60 or intron 63. Both western blot analysis and immunostaining demonstrated a higher expression in the intron 60 splitting vectors. This result strongly suggests that trans-splicing vectors should be constructed using the site that yields the highest mRNA.
In summary, we have developed a strategy to rationally design trans-splicing AAV vectors. This finding may have a broad impact on developing trans-splicing vectors for other large therapeutic genes (such as the cystic fibrosis transmembrane conductance regulator gene and the photoreceptor-specific ATP binding cassette transport gene for the treatment of cystic fibrosis and Stargardt disease, respectively) as well as the use of large complicated transcription regulatory elements in the AAV vector.
METHODS
Evaluation of the endogenous splicing signals. The exon-intron junctions flanking introns 53, 56, 60 and 63 of the human dystrophin gene were amplified by PCR from HEK293 cell genomic DNA (Supplementary Methods online). The double D-ITR junction was derived from a circular AAV genome isolated from infected muscle 15 . The mini-constructs for the RPA were assembled on pcDNA3.1(+) (Invitrogen) (Fig. 1) . A total of four plasmids were generated including (in the order of exon/intron/exon) p53/53/54, p56/56/57, p60/60/61 and p63/63/64. The templates for RPA probes were PCR amplified from each respective plasmid and cloned in pGEM3Z (Promega) (Supplementary Methods online). RPA probes (for the dystrophin gene and the endogenous human b-actin gene) were generated by in vitro transcription as described before 15 . RPA reaction and RNA signal quantification were carried out according to a published protocol 15 . Constructs generated by PCR amplification were validated by sequencing.
AAV vector and animal procedure. Two sets of trans-splicing vectors were generated based on the endogenous splicing signals from introns 60 and 63, respectively. Each set included a donor and an acceptor. These vectors were generated by first introducing the corresponding intron splicing sequences in the DH2 minigene. The intermediate constructs were then inserted into previously described multiple cloning AAV cis plasmids (Supplementary Methods online). AAV-6 packaging plasmids (pMTrep2 and pCMVcap6) were Figure 2 DH2 mini-dystrophin expression from two independent sets of trans-splicing AAV vectors. The EDL and the TA muscles of 2-month-old mdx mice were co-infected with 1 Â 10 10 vector genomes (vg) (for the EDL muscle) and 2 Â 10 10 vg (for the TA muscle) particles of each pair of transsplicing viruses. Single vector infection (donor or acceptor alone) was also included in the cohort study (5 Â 10 9 vg particles for the EDL muscle and 1 Â 10 10 vg particles for the TA muscle). Mini-dystrophin expression was evaluated 1 month later. (a) Schematic diagram of DH2 mini-dystrophin trans-splicing vectors (not drawn to scale). The donor virus carries the cytomegalovirus (CMV) promoter, the 5¢ portion of the DH2 minigene and the endogenous splicing donor signal (from intron 60 and 63, respectively). The acceptor virus carries the endogenous splicing acceptor signal from the same intron (60 and 63, respectively), the remaining minigene and the polyA sequence. The viruses are accordingly named after the respective intron. 
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gifts from A. Dusty Miller 23 . Pseudotyped recombinant AAV stocks were generated by quadruple plasmid transfection with the cis plasmid, pMTrep2, pCMVcap6 and pHelper (Stratagene) at a ratio of 1:1:3:3 in HEK293 cells.
Crude lysate was purified through three rounds of CsCl isopycnic ultracentrifugation and titrated by slot blot as we reported before 24 . All animal experiments were approved by the Animal Care and Use Committee at the University of Missouri and were in accordance with National Institutes of Health guidelines. The mdx mouse strain was originally purchased from the Jackson Laboratory. The experimental mice were obtained from breeding colonies established locally (Supplementary Note and Supplementary  Fig. 1 online) . Both experimental and breeding mice were housed in a specific-pathogen-free animal facility. AAV was delivered to the EDL and/or TA muscles of male mdx mice using previously described protocols 24, 25 . Both slow-and fast-type myofibers were transduced by AAV-6. However, there seemed to be a trend toward preferential transduction of fast type myofiber ( Supplementary Fig. 6 online).
Protein expression and morphology. Mini-dystrophin expression was evaluated by indirect immuofluorescence staining and western blot analysis 26, 27 . Antibodies used for these studies include Dys-3 (monoclonal, Novocastra, Newcastle, UK; 1:10 for immunostaining and 1:20 for western blot analysis, specific for human dystrophin N-terminal domain), Dys-2 (monoclonal, Novocastra, 1:30 for immunostaining and 1:100 for western blot analysis, specific for dystrophin C-terminal domain), Mandys 8 (monoclonal, Sigma; 1:100 for immunostaining, Equal amounts (5 Â 10 9 vg particles) of each virus were co-injected into the left EDL muscles of 2-month-old male mdx mice. 5 Â 10 9 vg particles of AV.Acceptor.60 was injected to the contralateral EDL muscles. Mini-dystrophin expression and sarcolemma integrity were examined 3 months later. Photomicrographs are from the representative EDL muscles. Sarcolemma leakage in injured myofibers is revealed by the uptake of immunoglobulin from circulation (anti-mouse IgG staining). Dystrophin expression is detected either by a polyclonal anti-N-terminal antibody (for both mini-dystrophin and revertant dystrophin) or a monoclonal anti-N-terminal antibody (only detects human dystrophin-derived mini-dystrophin). The overlay image of anti-mouse IgG staining (red) and polyclonal antibody immunostaining (green) illustrates the protection of the sarcolemma by minidystrophin. Monoclonal antibody immunostaining also reveals membrane leakage in injured myofibers (intense cytosolic staining, different from peripheral membrane staining of dystrophin). Inserts are high power photomicrographs of boxed areas in the corresponding panels. Arrow, immunoglobulin infiltration is prevented in transduced myofibers whereas surrounding cells were not protected. *, revertant myofibers. Scale bar, 400 mm for low power photomicrographs and 50 mm for high power inserts. (c) Quantitative evaluation of muscle pathology and muscle force in the EDL muscles described in panel b. Left panel, quantification of transduction efficiency (n ¼ 15 for co-infection, n ¼ 7 for acceptor only), central nucleation (n ¼ 5 for co-infection, n ¼ 7 for acceptor only), and IgG infiltration (n ¼ 5 for co-infection, n ¼ 4 for acceptor only); middle panel, specific muscle force (n ¼ 7 pairs); right panel, resistance to eccentric contraction-induced injury (n ¼ 7 pairs). *, the difference between co-infected muscle and single vector infected muscle was statistically significant. (d) Efficient mini-dystrophin expression in aged mdx EDL muscle moderately improved muscle function. The left EDL muscles of 1-year-old mdx mice were co-infected with 1.5 Â 10 10 vg particles of AV.Donor.60 and AV.Acceptor.60 (7.5 Â 10 9 vg particles each). The right EDL muscles were mock-infected with HEPES-buffered saline. Transgene expression, muscle pathology and muscle physiology were examined 6 months later. Left panel, representative photomicrographs of the EDL muscles either co-infected with both AV.Donor.60 and AV.Acceptor.60, or mock infected with HEPES saline. Immunostaining was performed with monoclonal anti-N-terminal antibody. Scale bar, 400 mm. Right panel, resistance to eccentric contraction-induced injury (n ¼ 3 for each group). *, the difference between co-infected muscle and saline-injected muscle was statistically significant according to paired t test. Cross, the results in BL10 muscle were significantly different from that in mdx muscle (both AAV infected and mock treated) according to one-way ANOVA and Bonferroni post hoc test. Pound, the result in BL10 was only significantly better than that of saline-injected mdx muscle according to one-way ANOVA and Bonferroni post hoc test.
specific for exon 32) and an affinity purified polyclonal anti-dystrophin N-terminal antibody (1:600 for immunostaining only) 17, 25 . Muscle microsome preparation was used for western blot analysis. Equal loading was confirmed by Ponseu S staining of the membrane and anti-b-catenin immunoblotting of stripped membranes (Supplementary Methods online) 28 . The DGC components were evaluated by immunostaining with monoclonal antibodies against b-dystroglycan (Novocastra, 1:50), b-sarcoglycan (Novocastra, 1:50), dystrobrevin (BD Bioscience; 1:200), and syntrophin (Abcam; 1:200). Transduction efficiency was determined by dividing the total number of Dys-3 positive cells (immunostaining) with the total number of myofibers (hematoxylin and eosin (H&E) staining of adjacent section). At least two montage composites of the entire cross sections in the mid-belly were quantified for each muscle sample. The percentage of centrally nucleated myofibers was determined as described before 25 . Standard histochemical procedures were used for HE, Masson trichrome and nonspecific esterase staining.
Muscle physiology. The EDL muscle was carefully isolated and mounted on a dual mode servomotor transducer (Aurora Scientific) in Ringer's solution.
Muscle stimulation, data acquisition and data analysis were conducted with DMC/DMA software (Aurora) (Supplementary Methods online) . The absolute muscle force was measured at 80, 120 and 150 Hz. The specific force was calculated by dividing the value of absolute force with muscle cross-sectional area (Supplementary Methods online) 25 . The eccentric contraction assay was performed according to a published protocol 25 .
Statistical analysis. Data are presented as the mean ± s.e.m. and analyzed with SPSS software. In studies involving two groups, comparisons were made using two-tailed t-tests (paired or unpaired depending on the situation). In studies involving multiple groups, comparisons were made using one-way ANOVA followed by Bonferroni post hoc test. Differences were considered significant when P o 0.05.
Note: Supplementary information is available on the Nature Biotechnology website.
